RBC Capital lowered the firm’s price target on Verastem (VSTM) to $12 from $16 and keeps an Outperform rating on the shares. The firm is updating its model after the approval of Av-Fak, ASCO data for Av-Fak in PDAC, and data from partnered G12D, the analyst tells investors in a research note. RBC adds that it sees significant upside in the pipeline, with potential for label expansions into PDAC or NSCLC.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Closing Bell Movers: FedEx slips 5% after results and guidance
- Verastem announces first patient dosed with VS-7375
- Verastem’s Strategic Growth and Promising Clinical Data Drive Buy Rating
- Promising Clinical Developments and Strong Valuation Support Buy Rating for Verastem
- Verastem’s Promising Clinical Advances and Strategic Developments Justify Buy Rating